Treatment with catestatin changes the proportion of two major phyla Bacteroidetes and Firmicutes in the gut microbiota in an opposite manner observed in intestinal disorders like IBD, IBS or non-intestinal disorders like obesity. Specifically, administration of an effective amount of catestatin increased the relative percentage of Bacteroidetes and decreased the relative percentage of Firmicutes in the gut microbiota.